| Nov 21 |
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
|
| Nov 21 |
Kura Oncology partners Kyowa Kirin to advance AML treatment
|
| Nov 20 |
Kura stock slides 17% on Kyowa Kirin deal for ziftomenib
|
| Nov 20 |
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
|
| Nov 9 |
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
|
| Nov 7 |
Kura Oncology: Q3 Earnings Snapshot
|
| Nov 7 |
Kura Oncology GAAP EPS of -$0.63 in-line
|
| Nov 7 |
Kura Oncology Reports Third Quarter 2024 Financial Results
|
| Nov 6 |
Kura Oncology Q3 2024 Earnings Preview
|
